5 Recommendations for data collection

5 Recommendations for data collection

5.1 Proposals for further data collection in the Cancer Drugs Fund include:

  • recurrence-free survival

  • distant metastases-free survival

  • overall survival

  • long-term follow-up of people who received pembrolizumab as an adjuvant treatment who develop advanced disease and receive pembrolizumab again to treat metastatic disease.

  • National Institute for Health and Care Excellence (NICE)